Bundle 5 (IC 2027)

Only available as part of a package
Joanne Jeter, MD, MS

Joanne Jeter, MD, MS

Medical Oncologist, Clinical Cancer Geneticist

City of Hope

Joanne Jeter, MD, MS (she/her) is a board-certified medical oncologist and clinical cancer geneticist. She started working at City of Hope on October 16, 2023, and is very excited about joining many of her friends in this prestigious group. Her medical school training was at the University of Texas-Houston Health Sciences Center. She subsequently completed her residency in Internal Medicine at the University of Alabama-Birmingham. While she was in her Medical Oncology fellowship program at the University of Michigan, she was fortunate to start working with Dr. Stephen Gruber's clinical cancer genetics program, and this has been her primary focus since that time. She has also earned a Master's degree in Clinical Trials Design and Statistical Analysis at the University of Michigan. Prior to her time at City of Hope, she was the Medical Director for the Family Cancer Assessment Clinic at Huntsman Cancer Institute at the University of Utah. She has also worked as a medical oncologist and clinical cancer geneticist at the University of Arizona and the Ohio State University.

Key:

Complete
Failed
Available
Locked
Clinical Management of Hereditary Breast Cancer
Begin self-paced component package.
Begin self-paced component package. The Original Release Date for this Module is April 2026. CME Termination Date for this Module is April 2029.
You must register to access.
IC 27 - Bundle 5 Quiz
4 Questions  |  Unlimited attempts  |  5/6 points to pass
4 Questions  |  Unlimited attempts  |  5/6 points to pass Select the appropriate response for each question. Correct responses will display after a passing score of 80% (6/7) is reached. Please retake the quiz until you pass.
You must register to access.
Bundle 5 Distance Learning Evaluation
6 Questions
6 Questions Please respond to the statements in this evaluation as they relate to your experiences with this week's distance learning modules. This survey will take less than 3 minutes to complete.
You must register to access.
Elective Modules
HBOC Clinical Management and Precision Medicine: Evidence-based Updates, Part 1
Open to view video.  |  49 minutes
Open to view video.  |  49 minutes Review NCCN guidelines for high-risk cancer screening and management. Identify the methods and efficacy of breast and gynecologic screening tools. Identify the methods and efficacy of breast and ovarian surgical risk reduction. Understand the potential impact of cancer risk assessment and genetic testing related to surgical decision-making and timing. Recognize emerging role of targeted therapies for high-risk individuals (e.g., BRCA, PTEN, etc.).
You must register to access.
HBOC Clinical Management and Precision Medicine: Evidence-based Updates, Part 2 Chemoprevention
Open to view video.  |  58 minutes
Open to view video.  |  58 minutes Review chemopreventive clinical trials pertinent to individuals at high risk for developing cancer. Apply these data appropriately to individuals at genetic versus empiric high risk. Describe chemoprevention studies currently open for enrollment.
You must register to access.
Option: Traditional Version of Modules
Clinical Management of Hereditary Breast Cancer
Open to view video.  |  67 minutes
Open to view video.  |  67 minutes • Review the tools for high-risk breast and ovarian cancer screening • Identify the role and efficacy of breast and ovarian cancer surgical risk reduction • Recognize the role of chemoprevention options for breast and ovarian cancer risk reduction • Use evidence-based guidelines to inform risk management recommendations for patients with pathogenic variants in high or moderate penetrance breast and ovarian cancer susceptibility genes • Apply individualized screening and risk management options and recommendations to case examples
You must register to access.